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Abstract
Objectives. To develop a quantitative score based on colour duplex sonography (CDS) to predict the diagnosis
and outcome of GCA.
Methods. We selected patients with positive CDS and confirmed diagnosis of GCA recruited into the TA Biopsy
(TAB) vs Ultrasound in Diagnosis of GCA (TABUL) study and in a validation, independent cohort. We fitted four
CDS models including combinations of the following: number and distribution of halos at the TA branches, average
and maximum intima–media thickness of TA and axillary arteries. We fitted four clinical/laboratory models. The
combined CDS and clinical models were used to develop a score to predict risk of positive TAB and clinical out-
come at 6 months.
Results. We included 135 GCA patients from TABUL (female: 68%, age 73 (8) years) and 72 patients from the in-
dependent cohort (female: 46%, age 75 (7) years). The best-fitting CDS model for TAB used maximum intima–media
thickness size and bilaterality of TA and axillary arteries’ halos. The best-fitting clinical model included raised in-
flammatory markers, PMR, headache and ischaemic symptoms. By combining CDS and clinical models we derived
a score to compute the probability of a positive TAB. Model discrimination was fair (area under the receiver operat-
ing characteristic curve 0.77, 95% CI: 0.68, 0.84). No significant association was found for prediction of clinical
outcome at 6 months.
Conclusion. A quantitative analysis of CDS and clinical characteristics is useful to identify patients with a positive
biopsy, supporting the use of CDS as a surrogate tool to replace TAB. No predictive role was found for worse
prognosis.
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Rheumatology key messages
. Quantitative analysis of ultrasound findings informs on the diagnosis of giant cell arteritis (GCA).
. A computable score provides risk-stratification of a positive temporal artery biopsy diagnostic for GCA.
. Prognostic role of baseline ultrasound quantitative findings in GCA needs to be further addressed.
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Introduction
An increasing body of evidence supports the role of col-
our duplex sonography (CDS) as a diagnostic tool for
GCA [1–5]. CDS detects inflammatory changes as a
homogeneous hypoechoic vessel wall swelling, known
as a ‘halo-sign’ [3, 6]. Ultrasound offers the advantage
of being a safe, repeatable and less costly procedure
than TA biopsy (TAB), allowing us to assess the tem-
poral arteries (TA) and extra-cranial vessels at the same
time [4, 7]. TAB has been the standard diagnostic tool
for GCA for several years, but imaging, performed with
the correct expertise, is emerging as a more effective
and versatile method [3]. The combined examination of
TA and axillary arteries (AX) represents the minimum
ultrasonographic core assessment of patients with sus-
pected GCA and is known to increase the diagnostic
yield in large vessel vasculitis [8]. CDS has been demon-
strated to have higher sensitivity compared with TAB,
which is still recognized as the gold standard for the
diagnosis of GCA [4, 9]. Nevertheless, the role of CDS in
the follow-up of patients and its predictive value on out-
come are still poorly understood.
Available CDS data across studies are largely qualita-
tive, with a binary (positive/negative) assessment of
CDS results. A ‘positive’ CDS supporting a diagnosis of
GCA has been defined, qualitatively, as the presence of
a halo at one or more vascular sites [6, 7]. However, the
value of specific CDS findings such as halo size (max-
imum or average thickness), number of TA branches
involved, total number of anatomical sites with halo, or
the presence of bilateral halos in predicting diagnosis
and outcome are still to be defined. Moreover, a stand-
ardized, quantitative score to grade the severity and ex-
tent of vascular involvement detected by CDS in GCA
has not yet been developed.
We therefore analysed data from a large prospective
multicentre study including new cases of suspected
GCA, the TA Biopsy vs Ultrasound in Diagnosis of GCA
(TABUL) study [4], to determine the association of ultra-
sonographic parameters with clinical, histological and
outcome findings, and to develop a comprehensive CDS
score. We then tested the ultrasonographic models on
an independent cohort of patients newly referred for
suspected GCA.
Methods
Patients were selected among those recruited in the
TABUL study [4]. According to the study design,
patients with a suspected diagnosis of new-onset GCA
had undergone both ultrasound and TAB within 7 days
of commencing high-dose glucocorticoids (GC). The
detailed methods and results of the TABUL study have
been previously described [4]. We selected patients with
a positive CDS and a confirmed final diagnosis of GCA.
We identified an independent cohort of patients referred
to the fast-track GCA clinics of the Rheumatology
departments of the University of Oxford and the
University of Pavia between March 2016 and November
2017 who had a positive CDS and a confirmed diagno-
sis of GCA. The two recruiting centres applied the same
CDS methodology as TABUL [10].
A positive CDS was defined by the presence of at
least one site with a halo at the level of the TA, or at
least one AX showing a halo. A halo was defined as
a homogeneous, hypoechoic wall thickening, well
delineated towards the luminal side, visible on both
planes (longitudinal and transverse), most commonly
concentric [4, 6, 7]. Among ultrasound abnormalities
recorded in the TABUL study, we selected the specific
finding of the presence or absence of a halo. Halo thick-
ness was recorded as the maximum thickness, meas-
ured in millimetres (mm), of the intima–media complex
on the wall distal to the probe on longitudinal planes.
Intima–media thickness (IMT) was measured at the site
with the maximum size of the intima–media complex.
The presence of bilateral halos in the TA was defined as
the finding of a bilateral halo in at least one of the
branches (common, parietal, frontal) of each TA.
Bilateral halo on AX was defined by the involvement of
both AX.
To assess the discriminatory ability of the CDS
parameters on diagnosis, we included patients with a
positive CDS, but in whom a diagnosis of GCA had
been excluded. For the association with clinical features
(histological findings and outcome) we considered
patients with a confirmed diagnosis of GCA, defined by
final physician’s diagnosis during follow-up visits [4].
Clinical evaluations included details on presenting
symptoms, ongoing manifestations on the day of the
CDS assessment, physical examination of the TA and
information on therapy. Patients provided written
informed consent prior to inclusion in the study. Ethical
approval was obtained for the study (REC No. 09/
H0505/132).
Disease activity was calculated using the BVAS col-
lected at 2-week (for TABUL only) and at 6-month
examinations (for both cohorts). The Vasculitis Damage
Index and its individual items were considered at the 6-
month visit.
Statistical analysis
Data were analysed using Stata 15.1 (StataCorp,
College Station, TX, USA). Continuous variables are pre-
sented as mean (S.D.) or median values. For categorical
variables, absolute and relative frequencies are reported.
Differences in the CDS variables according to several
clinical, laboratory, histological and outcome character-
istics were tested using the Wilcoxon–Mann–Whitney
test for continuous variables and the v2 test or Fisher’s
exact test for dichotomous variables.
In order to identify a comprehensive score inclusive of
different ultrasonographic parameters that could be
combined with clinical and laboratory findings, we fitted
the CDS logistic models against two major outcomes:
TAB diagnostic for GCA and clinical outcome at
6 months [defined as visual loss, Vasculitis Damage
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Index ocular items, GC >10 mg/day of prednisone-
equivalent (based on median value for TABUL cohort)
at 6 months and/or the need for adjunctive immunosup-
pressants]. We also fitted clinical logistic models against
TAB diagnostic for GCA and clinical outcome at
6 months.
The variables to be included in these models were
identified a priori based on the available evidence or the
hypothesized clinical evidence. We then combined the
best CDS and clinical models (according to the Akaike
information criterion, the lower the better) to identify in-
dependent correlates of a TAB diagnostic for GCA and
of clinical outcome at 6 months. The best-fitting CDS
and clinical/laboratory models were combined to de-
velop a comprehensive score (the GCA-US score). For
model discrimination we computed the model area
under the receiver operating characteristic (ROC) curve
and its 95% CI. The final model was validated with a
10-fold cross-validation.
We tested the association between the GCA-US score
and the clinical outcome at 6 months on the independ-
ent cohort.
Results
We included 135 patients recruited in TABUL (female:
92, mean age 73 (8) years) who had a positive CDS and
a diagnosis of GCA. In order to assess the discrimin-
atory ability of CDS on diagnosis, we compared these
patients with an additional 44 patients (24%) who had a
positive CDS showing a halo, but did not have a final
diagnosis of GCA. Of the 135 patients, 128 (95%) were
recorded as having a halo in at least one site of a TA (ei-
ther the common trunk, parietal or frontal rami); bilateral
halos were present in 71 of these cases (52%). Thirty-
seven patients (27%) had AX involvement, of whom 16
(12%) had bilateral halos of the AX. Among the patients
with a positive CDS of the AX, only 7 (5%) had exclusive
AX involvement.
The independent cohort consisted of 72 patients (fe-
male: 33; mean age 75 (7) years) with a confirmed clinical
diagnosis of GCA and a positive CDS. Five subjects
with a positive CDS were diagnosed as not having GCA.
Sixty-three patients (87%) had at least one site with a
halo at the TA (bilateral in 54% of cases). Twenty-four
patients (33%) had AX involvement (bilateral in 8%).
Only 6 patients had isolated AX involvement (8%).
Detailed frequencies of CDS findings and halo charac-
teristics in each cohort are presented in Table 1. The
distribution of patients according to the number of sites
with halos for each cohort is presented in
Supplementary Fig. S1, available at Rheumatology on-
line. One vascular site showing a halo was recorded for
28% of patients in TABUL and 35% in the independent
cohort. Two sites with a halo were recorded in 21% and
29% of patients, respectively. Only a minority of patients
showed active involvement in more than six vascular
sites (4.4% in TABUL and 0% in the independent
cohort).
The clinical characteristics of the populations included
in the analysis are presented in Table 2. Patients were
more frequently female in TABUL compared with the in-
dependent cohort (68% vs 46%; P ¼ 0.002); there were
no significant differences in age between the two
cohorts. The mean duration of GC treatment prior to
CDS assessment was significantly longer in the inde-
pendent cohort (14.5 (15.5) vs 1.9 (1.8) days; P < 0.001);
however, GC had been prescribed significantly more fre-
quently to patients enrolled in TABUL compared with
the independent cohort (74% vs 53%; P ¼ 0.003).
Clinical presentation differed in terms of frequency of
systemic symptoms (58% of cases in TABUL vs 19% in
the independent cohort; P < 0.001) and PMR features,
less frequently reported in TABUL patients (18% vs
44%; P ¼ 0.0001). There were no significant differences
regarding ischaemic symptoms at presentation or rate
of permanent visual loss between the two cohorts.
The complete descriptive analyses of CDS findings
(number of sites with halo and halo size) according to
clinical diagnosis, specific TAB findings and clinical
presentation are described in Supplementary Tables S1
and S2, available at Rheumatology online, for TABUL
cohort and Supplementary Tables S3 and S4, available
at Rheumatology online, for the independent cohort.
Ultrasound and clinical models (TABUL cohort)
The association of the four ultrasound models was
tested against two main outcomes: the biopsy outcome
(TAB diagnostic for GCA), n¼ 76 patients (56%), and the
clinical outcome (composite prognostic measure at
6 months from diagnosis), n¼ 55 patients (41%)
(Table 3). There was a significant association between
total number of halos, halo thickness at the level of the
TA and bilateral TA halos with the biopsy outcome. The
best model (with the lowest Akaike information criterion)
for a positive TAB included a combination of the follow-
ing variables: maximum IMT at the TA >0.70 mm, bilat-
eral TA halos, maximum AX IMT >1.30 mm and bilateral
AX halos (model 4 CDS).
The association of the four clinical models was tested
against the same two main outcomes. The best model
(with the lowest Akaike information criterion) included
the number of ischaemic symptoms at presentation,
PMR symptoms and elevated ESR/CRP values (model 3
clinical). None of the clinical models reached statistical
significance in predicting the biopsy outcome, although
a significant association of elevated ESR/CRP values
with the biopsy outcome was reported. None of the clin-
ical models predicted the clinical outcome at 6 months,
with only systemic symptoms showing significant asso-
ciation with the 6-month outcome (Table 4).
GCA-US score
By combining the best-fitting CDS and clinical models
(Table 4) we derived a simple score to compute the
probability of a positive biopsy. The final model area
under the ROC curve was 0.77 (95% CI: 0.68, 0.84);








atology/article/59/9/2299/5680051 by guest on 08 M
arch 2021
after 10-fold cross-validation it became 0.66 (95% CI:
0.55, 0.76).
The score can be easily computed using the algorithm
shown in Fig. 1 (left panel) and the expected probability
of positive biopsy is derived from Fig. 1 (right panel).
Two simulated cases are reported.
Application of the ultrasound and clinical models on
the independent cohort
The CDS and clinical models were used to assess the
association with the clinical outcome at 6 months in the
independent cohort confirming the lack of association
(Supplementary Tables S5 and S6, available at
Rheumatology online).
To overcome the lack of TAB data in the independent
cohort, we tested whether the predictive probability of a
positive biopsy (given the clinical and CDS information)
was different between the two cohorts by applying the
GCA-US score, and found that there was no difference
in the probability of having a positive TAB if the patients
from the independent cohort had undergone a biopsy
(mean probability of a positive TAB in TABUL 0.64 (0.22)
compared with 0.61 (0.21) in the independent cohort;
P ¼ 0.254).
Given the absence of TAB data in this cohort, we
could not formally validate the GCA-US score on an in-
dependent cohort.
Discussion
To the best of our knowledge, this was the first study to
assess the role of quantitative information on the local-
ization and degree of vascular involvement detected by
CDS in patients with GCA. Our study demonstrates that
a comprehensive analysis of specific CDS quantitative
findings rather than a simple binary (positive/negative)
approach can add value to the diagnostic role of ultra-
sound in the assessment of GCA.
In this study we identified the best CDS and clinical
characteristics to identify patients with a positive TAB;
these were combined in a comprehensive GCA-US
score to assess the probability of a positive biopsy.
However, the same models were not able to discrimin-
ate the clinical outcome at 6 months.
The gold standard for the diagnosis of GCA is still
represented by characteristic histological findings on
TAB [11]; however, the unsatisfactory sensitivity of this
test prompted the search for more reliable, rapid and
less invasive diagnostic tools. TABUL was the first
study to systematically compare the role of CDS vs
TAB in a prospective, multicentre cohort study [4]. The
TABUL study demonstrated that ultrasound has a
higher sensitivity (but lower specificity) compared with
TAB. CDS was indeed more likely than TAB to provide
evidence for a diagnosis of GCA, with a fair level of
agreement between the two tests (30% discordance).
Our study analysed this association in further detail by
TABLE 1 Frequencies of ultrasound findings and halo characteristics considered for the analysis in the two cohorts
Frequency and halo size
CDS variable Detailed description TABUL Independent cohort
Overall number of
sites with halo
Number of sites with halo in
TA þ number of sites with
halo in AX
128 patients with halo in TA þ 37
with halo in AX; min 0, max 8
sites
63 patients with halo in TA þ 24
with halo in AX; min 0, max 6
sites
Number of halos in
TA
Sum of sites with halo in TA 128 patients with halo in TA; min
0, max 6 sites





among sites with halo in TA
Data available for 125 patients;
average 0.6 (0.28) mm
Data available for 63 patients;




among sites with halo in AX
Data available for 37 patients;
average 1.3 (0.85) mm
Data available for 24 patients;




among sites with halo in TA
Data available for 125 patients;
min 0.1, max 3.2 mm
Data available for 63 patients;




among sites with halo in AX
Data available for 37 patients;
min 0.6 mm, max 6.7 mm
Data available for 37 patients;
min 1.0 mm, max 2.4 mm
Bilateral halo in TA Defined as the presence of a
bilateral halo on any branch
of the TA
71 of 135 patients (52%) 39 of 72 patients (54%)
Bilateral halo in AX Defined as the presence of a
halo on both AX arteries
16 of 135 patients (12%) 6 of 72 patients (8%)
AX: axillary artery; CDS: colour duplex sonography; TABUL: TA Biopsy vs Ultrasound in Diagnosis of GCA.
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TABLE 2 General characteristics of the two cohorts with newly suspected and clinically proven GCA patients
Patients with GCA with positive CDS
TABUL Independent cohort P-value
(n 5 135) (n 5 72)
Female, n (%) 92 (68) 33 (46) 0.002
Age, mean (S.D.), years 73 (8) 75 (7) 0.086
High-dose GC prior to CDS, n (%) 100 (74) 38 (53) 0.003
Number of days on GC on the day of CDS scan, mean (S.D.) 1.9 (1.8) 14.5 (15.5) <0.001
TAB findings, n (%)
TAB diagnostic for GCA 76 (56) NAa
Media infiltrate 20 (15) NA
Transmural infiltrate 26 (19) NA
Small vessel or adventitia 18 (13) NA
Laboratory findings/symptoms, n (%)
Elevated ESR/CRPb 131 (97)c 70 (97)c 1
General symptoms pre-GC 96 (71) 29 (40) <0.001
Headache pre-GC 93 (69) 57 (79) 0.126
Jaw claudication pre-GC 62 (46) 37 (51) 0.494
Visual symptoms pre-GC 57 (42) 40 (56) 0.055
PMR pre-GC 25 (18) 32 (44) 0.0001
General symptoms current on day of CDS 78 (58) 14 (19) <0.001
Headache current on day of CDS 69 (51) 35 (49) 0.784
Jaw claudication current on day of CDS 39 (29) 19 (26) 0.647
Visual symptoms current on day of CDS 30 (22) 18 (25) 0.626
PMR current on day of CDS 24 (18) 20 (28) 0.096
Any visual lossd 22 (16) 18 (25) 0.117
Ischaemic symptoms at presentation (jaw/tongue
claudication, amaurosis fugax, double vision, stroke)
81 (60) 50 (69) 0.226
Number of ischaemic symptoms at presentation, n (%) 0.205
0 54 (40) 22 (31)
1 39 (29) 29 (40)
2 37 (27) 16 (22)
3 5 (4) 5 (7)
BVAS 6 months, n (%)
BVAS ocular 11 (8) 7 (10) 0.627
BVAS nervous 11 (8) 19 (26) 0.0004
BVAS¼0 93 (69) 39 (54) 0.033
BVAS 1 28 (21) 26 (36) 0.019
BVAS 5 12 (9) 3 (4) 0.187
BVAS 10 2 (1) 0 NA
VDI 6 months, n (%)
VDI¼0 77 (57) 36 (50) 0.336
VDI¼1 29 (21) 17 (24) 0.621
VDI¼2 10 (7) 3 (4) 0.386
VDI¼3 1 (0.7) 3 (4) 0.093
VDI¼4 3 (2) 2 (3) 0.652
VDI¼5 1 (0.7) 1 (1) 0.818
VDI diplopia 12 (9) 12 (17) 0.089
VDI blindness 13 (10) 12 (17) 0.147
GC >10 mg/day at 6 months 39 (29) 25 (35) 0.375
Adjunctive immunosuppressive drug at 6 monthse 12 (9) 34 (47) <0.001
aIn the independent cohort of patients with GCA, only one TAB was performed (and without any artery obtained in the
specimen). bElevated ESR/CRP: ESR >15 mm/h and or CRP >5 mg/L. cData not available for two patients. dAny visual
loss defined as: permanent visual loss in at least one eye and/or evidence of anterior ischaemic optic neuropathy due to
GCA. eTABUL: methotrexate (n¼10); leflunomide (n¼2). Independent cohort: methotrexate (n¼32); leflunomide (n¼1); IL-
6 inhibitor (n¼1). CDS: colour duplex sonography; GC: glucocorticoids; NA: not available; TAB: TA biopsy; TABUL: TA
Biopsy vs Ultrasound in Diagnosis of GCA; VDI: Vasculitis Damage Index.
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TABLE 4 Association between the clinical combined models and the biopsy and clinical outcome—TABUL cohort
Clinical models Biopsy outcome
(TAB diagnostic for GCA)
Clinical outcome (visual loss 1 more
intensive treatment at 6 months)
OR 95% CI AIC P-value OR 95% CI AIC P-value
Model 1 clinical 148.77 0.707 Model 1 clinical 147.85 0.688
Any ischaemic
symptomsa
1.30 0.56, 3.05 0.542 Any ischaemic
symptomsa
2.27 0.97, 5.31 0.059
PMR 0.62 0.23, 1.68 0.342 PMR 1.21 0.45, 3.25 0.707
Elevated ESR/CRPb 2.96 1.32, 6.66 0.009 Elevated ESR/CRPb 0.50 0.22, 1.12 0.093
Model 2 clinical 149.14 0.824 Model 2 clinical 147.36 0.599
Systemic symptomsc 0.97 0.37, 2.52 0.951 Systemic symptomsc 2.69 1.01, 7.17 0.048
PMR 0.66 0.24, 1.85 0.434 PMR 1.06 0.39, 2.91 0.907
Elevated ESR/CRPb 2.81 1.26, 6.30 0.012 Elevated ESR/CRPb 0.47 0.21, 1.06 0.070
Model 3 clinical 147.59 0.189 Model 3 clinical 148.59 0.543
Number of ischaemic
symptomsa
1.33 0.84, 2.11 0.219 Number of ischaemic
symptomsa
1.46 0.94, 2.27 0.091
PMR 0.57 0.21, 1.58 0.278 PMR 1.20 0.44, 3.24 0.719
Elevated ESR/CRPb 3.02 1.34, 6.78 0.008 Elevated ESR/CRPb 0.46 0.21, 1.03 0.059
Model 4 clinical 149.09 0.551 Model 4 clinical 147.86 0.697
Headache 0.90 0.36, 2.21 0.815 Headache 2.37 0.96, 5.87 0.061
PMR 0.68 0.25, 1.84 0.442 PMR 1.17 0.43, 3.15 0.762
Elevated ESR/CRPb 2.79 1.25, 6.21 0.012 Elevated ESR/CRPb 0.46 0.21, 1.04 0.062
aIschaemic symptoms: presentation with jaw or tongue claudication, amaurosis fugax, double vision, stroke. bESR
50 mm/h and/or CRP >40 mg/L. cSystemic symptoms: fever, weight loss, night sweats. AIC: Akaike information criterion;
TAB: TA biopsy; TABUL: TA Biopsy vs Ultrasound in Diagnosis of GCA.
FIG. 1 GCA-US score
Combination of ultrasonographic and clinical models to stratify patients according to the risk of having a positive TA
biopsy. aVisual: double vision, amaurosis fugax. APR: acute phase reactants; AX: axillary artery; IMT: intima–media
thickness; TA: temporal artery.
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exploring the role of specific CDS findings and not just
the presence/absence of a halo. We demonstrated that
several CDS parameters representing the extent of vas-
cular involvement (total number of sites with halo, num-
ber of halos at the TA, bilateral TA halos) and the
degree of vessel wall inflammation (maximum IMT at
the TA) are strongly associated with a TAB consistent
with GCA. The increase in specificity up to 100% in the
presence of bilateral TA halos has been previously
reported [12]; however, the association in terms of
number and size of halos is new. Our findings suggest
that having more widespread vessel involvement with a
higher number of sites with halos and having a more
prominent halo at the level of the TA correlate with the
histological diagnosis of GCA. An increasing interest in
the IMT size and its potential role in the diagnosis and/
or monitoring of disease is emerging. Recently, cut-off
values to distinguish IMT of patients with GCA from
matched controls without vasculitis have been formally
addressed in a prospective study demonstrating that
halo thickness can be useful in distinguishing patho-
logical cases from normal findings [13]. IMT of TA and
AX has been analysed to identify the cut-off value
ensuring the best diagnostic performance (using clinical
diagnosis as the reference standard) finding IMT sizes
in line with the values used in our study (0.7 mm for
TA and 1.2 mm for AX) [14].
All this evidence clarifies the association between
CDS and TAB and supports what is becoming more
common practice in centres with expertise in vasculitis
imaging; that is to avoid TAB in patients with a clinically
suggestive picture and a positive ultrasound [3]. Based
on the association of the ultrasound models and several
clinical and laboratory findings, we have identified a
comprehensive score that best fitted with the outcome
of a positive TAB. The comprehensive GCA-US score,
by combining the maximum IMT size and bilaterality of
halos at the level of the TA and AX with relevant clinical
or laboratory variables (raised inflammatory markers,
headache, ischaemic symptoms, PMR) provides a com-
putable estimate of the probability of a positive hist-
ology, supporting the use of CDS as a surrogate
diagnostic tool to replace TAB.
In the management of GCA we are in urgent need of
clinical, laboratory or imaging biomarkers that would
predict, at baseline, the subsequent outcome of dis-
ease. In our study, we did not identify any baseline CDS
or clinical parameter that could predict a worse outcome
at 6 months (visual sequelae and/or the need for more
intensive treatment). In line with our findings, Schmidt
et al. [15] had previously assessed a large cohort of
consecutive patients with GCA and found no statistically
significant association between number of pathological
TA segments, presence of stenoses or bilateral findings
and ophthalmic complications. We did not confirm the
findings from Czihal et al. [16] who had reported a
poorer response to treatment after a mean follow-up of
over 2 years in 43 GCA patients with extra-cranial large
vessel involvement. The shorter follow-up in our two
cohorts might explain the different results. It is possible
that the long-term consequence of higher degree of dis-
ease extent at baseline only becomes apparent after a
longer follow-up, once the dose of GC has been signifi-
cantly reduced. Nonetheless, these results might also
suggest that CDS findings do not fully capture the com-
plexity and severity of disease and, until further evi-
dence is collected, underscore the need to always
correlate imaging findings with the clinical picture and
clinician’s judgement.
Our study has some limitations. Some baseline charac-
teristics of the two cohorts (TABUL and independent co-
hort) are different, particularly concerning the frequency of
female patients and the number of days on GC treatment
at the time of CDS assessment. However, the independent
cohort reflects common clinical practice and represents
the setting in which to apply the evidence gathered from
standardized clinical studies. The need for more intensive
treatment at the end of follow-up as a measure of worse
prognosis can be considered a reliable indicator of a
higher GC-dependent disease or more relapsing disease,
but may also be biased by the treating physician’s prac-
tice; nevertheless, the inclusion of patients enrolled in
TABUL and of an independent cohort applying the same
methodology should have limited too much variability.
Finally, the short-term follow-up (6 months) might have pre-
cluded the recognition of some potential associations be-
tween ultrasound findings and long-term outcome, which
will need to be addressed by further studies. This might
limit prognostic ability of our tool based on a combined
end point of ischaemic complications or need for intensi-
fied treatment. Finally, it is important to remember that
TABUL data were acquired before definitions of cut-off
data on IMT normal values were published. Minimum
TABUL requirements were the use of a linear probe with
grey-scale frequency of at least 10 MHz. Nevertheless,
replication of the data in the more recent independent co-
hort with higher frequency probes (18 MHz) reached the
same conclusions as those of the TABUL data.
Conclusions
In conclusion, we have demonstrated that the quantitative
analysis of CDS findings (bilaterality of halos, IMT size)
provides important information that can be used to sup-
port the diagnosis of patients with GCA. A simple score
combining ultrasonographic and clinical information allows
for a predictable risk assessment of the probability of hav-
ing a positive TAB and supports the role of CDS in the
diagnosis of GCA. The prognostic role of quantitative CDS
findings needs to be addressed by long-term studies.
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